One of the reasons why hospital readmissions for the elderly are remaining high may be posthospital syndrome; priority review vouchers, which can be awarded by the FDA to 1 company and sold for a hefty price to another, are commanding a lower price than in past years; almost 8 months after Amazon, JP Morgan Chase, and Berkshire Hathaway announced their joint healthcare venture, there is little public information about it.
Despite Medicare penalizing hospitals for 30-day readmissions, the rate remains stubbornly high. According to The New York Times, that rate may be a result of posthospital syndrome, a vulnerable state that leaves the elderly disoriented and weak after being discharged from the hospital. According to 1 expert, hospital discharge marks the start of a period of vulnerability that can last 60 to 90 days. This period increases the patient’s risk of developing other health problems stemming from the stress of hospitalization.
Priority review vouchers (PRVs) can be redeemed to shorten the review times for certain drugs, and they can be sold. However, these vouchers are commanding lower prices, suggesting they may be valued less as the FDA issues more of them, reported Biopharma Dive. In 2015, a PRV was sold for $350 million, but the most recent one sold only fetched $80.6 million. The FDA awarded 6 PRVs throughout all of 2017, and it has already given out 5 in 2018.
When Amazon, JP Morgan Chase, and Berkshire Hathaway first announced its joint venture to addressing rising healthcare costs, there was great speculation about what the companies might be able to achieve. Almost 8 months later, there is still little public information about the venture. STAT took a look at what is known about the venture and what the nonprofit’s goal might really be. While Atul Gawande, MD, who was named CEO of the venture in June, said the company will stand apart from the 3 companies funding it, an insider did explain that solutions put in place must be vetted and considered by Amazon, JP Morgan, and Berkshire, first.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen